

Trust Headquarters  
 Russell's Hall Hospital  
 Dudley  
 West Midlands  
 DY1 2HQ

**Ref:** FOI-122025-0002108

**Date:** 14.1.26

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

I have a freedom of information request regarding the treatment of Multiple Myeloma. Could you please answer the following questions.

Q1. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:

- Belantamab Mafodotin [Blenrep] 0
- Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone 1
- Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone 0
- Bortezomib [Velcade] ± Dexamethasone 0
- Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) 0
- Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) 0
- Carfilzomib [Kyprolis] + Dexamethasone 0
- Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) 0
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) 18
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) 3
- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) 34
- Daratumumab [Darzalex] monotherapy 4
- Elranatamab 0
- Idecabtagene vicleucef [Abecma] 0
- Isatuximab [Sarclisa] +Bortezomib[Velcade] +Lenalidomide[Revlimid] +Dexamethasone (Isa-VRd) 1
- Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) 3
- Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) 4
- Lenalidomide [Revlimid] + Dexamethasone 20
- Lenalidomide [Revlimid] monotherapy 14
- Panobinostat + Bortezomib + Dexamethasone 3
- Pomalidomide [Imnovid] + Dexamethasone 5
- Selinexor + Bortezomib [Velcade] + Dexamethasone 1
- Selinexor + Dexamethasone 1
- Talquetamab 1
- Teclistamab [Tecvayli] 3
- Any other systemic anti-cancer therapy [please specify]
- Cyclophosphamide Oral 1

- DT-Pace 2
- Melphalan 7
- VCd 2
- Radar Trial 18

Q2. In the last 6 months, how many patients have been initiated\* on the following regimens?

- Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) 0
- Carfilzomib [Kyprolis] + Dexamethasone 0
- Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) 0
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) 2
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd) 0
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) 1
- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) 10
- Isatuximab [Sarclisa] +Bortezomib[Velcade] +Lenalidomide[Revlimid] +Dexamethasone (Isa-VRd) 0
- Lenalidomide [Revlimid] monotherapy 1
- Lenalidomide [Revlimid] + Dexamethasone 1
- Selinexor + Bortezomib [Velcade] + Dexamethasone 0
- Selinexor + Dexamethasone 0
- Any other systemic anti-cancer therapy [please specify]
- VCd 2
- Daratumumab Monotherapy 0
- DT-Pace 1
- Isatuximab+Pomalidamide+Dexamethasone 1
- Melphalan 1
- Pomalidamide + Dex 4
- Radar Trial 3
- Talquetamab 1
- Teclistamab 1

\*Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) during the calendar year 2025 prior to initiation.

Q3. In the last 6 months, how many patients have received the following second-line treatment?

- Lenalidomide [Revlimid] + Dexamethasone 10

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
 Trust Headquarters  
 Russell's Hall Hospital  
 Dudley  
 West Midlands  
 DY1 2HQ  
 Email: [dqft.dpo@nhs.net](mailto:dqft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

FOI/REF

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team**  
**The Dudley Group NHS Foundation Trust**